Quality indicators for the management of muscle-invasive bladder cancer in the perioperative setting of radical cystectomy: a narrative review

Frederik König¹,², Benjamin Pradere¹, Nico C. Grossmann¹,³,⁴, Fahad Quhal¹,⁵, Pawel Rajwa¹,⁶, Ekaterina Laukhtina¹,⁷, Keiichiro Mori¹,⁸, Satoshi Katayama¹,⁹, Takafumi Yanagisawa¹,⁸, Hadi Mostafai¹,¹⁰, Reza Sari Motlagh¹,¹¹, Abdulmajeed Aydh¹,¹², Roland Dahlem², Shahrokh F. Shariat¹,⁷,¹³,¹⁴,¹⁵,¹⁶, Michael Rink²

¹Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; ²Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; ³Department of Urology, University Hospital Zurich, Zurich, Switzerland; ⁴Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland; ⁵Department of Urology, King Fahad Specialist Hospital, Dammam, Saudi Arabia; ⁶Department of Urology, Medical University of Silesia, Zabrze, Poland; ⁷Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia; ⁸Department of Urology, The Jikei University School of Medicine, Tokyo, Japan; ⁹Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan; ¹⁰Research Center for Evidence Based Medicine, Tabriz University of Medical Sciences, Tabriz, Iran; ¹¹Men's Health and Reproductive Health Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran; ¹²Department of Urology, King Faisal Medical City, Abha, Saudi Arabia; ¹³Department of Urology, Weill Cornell Medical College, New York, New York, USA; ¹⁴Department of Urology, University of Texas Southwestern, Dallas, Texas, USA; ¹⁵Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic; ¹⁶Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan

Contributions: (I) Conception and design: F König, M Rink, SF Shariat; (II) Administrative support: B Pradere, R Dahlem, SF Shariat; (III) Provision of study materials or patients: None; (IV) Collection and assembly of data: F König, M Rink, SF Shariat; (V) Data analysis and interpretation: F König, B Pradere; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Correspondence to: Shahrokh F. Shariat, MD. Department of Urology, Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria. Email: shahrokh.shariat@meduniwien.ac.at.

Background and Objective: Identifying evidence-based and measurable quality-of-care indicators is crucial for optimal management of patients requiring radical cystectomy (RC) for muscle-invasive bladder cancer (MIBC). RC with urinary diversion and lymphadenectomy is the standard treatment for patients with MIBC. Preoperatively, neoadjuvant chemotherapy (NAC) with cisplatin-based combinations improves survival outcomes and is the recommended standard of care for eligible patients. Intraoperatively, lymph node dissection (LND) by, at least, following a standard pelvic lymph node template improves overall- and recurrence-free survival and allows for accurate tumour staging. Avoiding positive soft tissue surgical margins (STSM) should be a main target intraoperatively since they are almost universally associated with mortality. Implementing enhanced recovery after surgery (ERAS) programs can reduce lengths of hospital stay (LOS) and postoperative complication rates without increasing readmission rates after RC. Moreover, several studies have shown that smoking negatively affects local and systemic treatment outcomes in bladder cancer (BC) patients. Therefore, smoking cessation counselling for smokers should be an essential part of bladder cancer management regardless of the disease state.

Methods: We performed a comprehensive, non-systematic review of the latest literature to define indicators representing the best evidence available for optimal care of MIBC patients treated with RC.

Key Content and Findings: In this review, we propose five major quality indicators that are easily implementable for optimized management of MIBC patients treated with RC, including: usage of cisplatin-based NAC in eligible patients, assurance of negative STSM, performance of (at least) a standard pelvic template LND, implementation of ERAS strategies, and professional smoking cessation counselling.

Conclusions: Optimal management of MIBC needs to be framed by evidence-based, reproducible, and
measurable quality indicators that will allow for guidance and comparative effectiveness assessment of clinical practices; adherence to them is likely to improve patients’ prognoses by a tensible margin. For the treatment of MIBC patients with RC, we identified five essential quality indicators.

**Keywords:** Assessment; bladder cancer (BC); muscle-invasive bladder cancer (MIBC); cystectomy; radical cystectomy (RC); quality

Submitted Jun 29, 2021. Accepted for publication Feb 10, 2022.
doi: 10.21037/tcr-21-1116
View this article at: https://dx.doi.org/10.21037/tcr-21-1116

**Introduction**

Urothelial carcinoma of the bladder is a common malignancy. It ranks fourth most frequent of solid cancers in men and tenth most frequent in women, with approximately 83,000 new cases annually in the US (1,2). Around 21% of bladder cancer (BC) cases are muscle-invasive at diagnosis, and a significant proportion of high-risk non-muscle invasive bladder cancer progresses eventually to muscle-invasive bladder cancer (MIBC) (3-6).

The standard of care for localized MIBC is the administration of neoadjuvant cisplatin-based combination chemotherapy followed by radical cystectomy (RC) with lymph node dissection (LND) and urinary diversion (7,8). Depending on perioperative findings, adjuvant cisplatin-based combination chemotherapy might be an option in patients at high risk of relapse if no neoadjuvant chemotherapy (NAC) was given before surgery (7).

There are several guidelines created by the relevant national and international institutions that provide surveillance and treatment recommendations in order to improve care for BC patients (7-13).

However, adherence to these recommendations is inconsistent and suboptimal, with substantial variability in clinical practices and differences in practice patterns, costs, and outcomes (14-19).

To optimize compliance and patient-centred care, the usage of implementation science was proposed as a systematic process to better align practice patterns with risk-adapted, individual treatment recommendations (20).

To reach reproducible and comparable quality metrics in clinical practices and ensure outcomes at the highest possible level, consensus on evidence-based quality indicators and their constant adherence and measurement remain an unmet need. To address this need, we propose five key factors as essential quality indicators for the optimal management of MIBC and suggest their systematical assessment for every patient and reporting. We present the following article in accordance with the Narrative Review reporting checklist (available at https://tcr.amегroups.com/article/view/10.21037/tcr-21-1116/rc).

**Methods**

We performed a comprehensive, non-systematic review of the latest literature to define indicators that represent the best evidence available for optimal care of MIBC patients undergoing RC. We included relevant articles in English available in the MEDLINE/PubMed database up to 31 December 2021. Search terms included “radical cystectomy”, “muscle-invasive bladder cancer”, “outcome”, “management”, “quality”, and associated terms. Additionally, guidelines of the relevant urological societies and references of the selected articles were reviewed. In this article, we propose the selected indicators that may guide uro-oncologic physicians in their daily practice and as key reporting measures for future study designs (Table 1).

**Main body**

**N4C**

Despite radical removal of the urinary bladder with curative intent, patients with MIBC are at high risk for disease recurrence and progression. Indeed, RC alone with lymphadenectomy provides 5-year relapse-free survival (RFS) and overall survival (OS) estimates of only about 69% and 50% in the patients with muscle-invasive disease, respectively (21-26).

General advantages for chemotherapy in the neoadjuvant setting include better chemo-tolerability, early treatment of micrometastases, and an *in vivo* assessment of the response/
Despite Cisplatin-based neoadjuvant combination chemotherapy being a standard that should be recommended and offered to all eligible patients with MIBC, it remains underused, with only around 19% of eligible patients receiving it (7,8,27).

In 2003, the Southwest Oncology Group (SWOG) reported in a well-designed randomized controlled trial (RCT) comprising clinically MIBC patients, a median survival benefit of 31 months with methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) regimen prior to RC compared to local treatment alone (28). Moreover, there was a higher rate of pathologic complete response (pCR) (pT0) on the final specimen (38% vs. 15%) (28).

The most recent meta-analysis on NAC prior to RC in MIBC patients, which included 15 RCTs with 3,285 patients, showed a significant OS benefit for patients receiving cisplatin-based NAC before surgery compared to RC alone (HR =0.87; 95% CI: 0.79–0.96; P=0.004) (29). The best regimen to use, however, remains debated. Therefore, the authors performed another meta-analysis of 12 retrospective studies comparing MVAC with gemcitabine plus cisplatin/carboplatin (GC) without finding statistically significant differences with regard to pCR (GC vs. MVAC: OR =1.17; 95% CI: 0.92–1.50; P=0.37) and pathological downstaging (pDS) to non-muscle invasive disease (OR =1.07; 95% CI: 0.85–1.34; P=0.19). However, regarding OS, GC seemed inferior to MVAC (HR =1.26; 95% CI: 1.01–1.57) (29). Additionally, the first results of the phase-III-GETUG/AFU V05 VESPER Trial showed a higher local control rate (pCR and pDS) for dose-dense MVAC compared to GC, while an association with survival still has to be confirmed (30). However, since a relevant proportion of MIBC patients may not be eligible for cisplatin-based therapies, further investigations for the role of alternate regimens in the neoadjuvant setting are needed.

For example, promising data from the prospective phase-II PURE-01 study have been published with a pCR rate of 42% and pDS of 54% for the neoadjuvant use of pembrolizumab (31). Larger, well-controlled trials with long-term survival data are awaited to confirm these preliminary results and possibly add a new option to our neoadjuvant systemic therapy armamentarium.

In conclusion, based on solid, reliable, and sufficient evidence, cisplatin-based combination NAC should be used in every clinically eligible MIBC patient and is therefore proposed as a quality indicator in the preoperative setting prior to RC. Discussions regarding postoperative chemotherapy/immunotherapy may also become increasingly important in the coming years (32-34).

Surgical margin status

Positive soft tissue surgical margin status in patients undergoing RC is a strong predictor for a poor survival outcome and is almost invariably associated with disease-specific death (35-38). The incidence of positive soft tissue margins in RC specimens is reported in 4.2% to 13% in retrospective studies (36-41). Surgical experience is quintessential for optimal results, as studies from high case-load centres report lower positive rates (42). For example, the Memorial Sloan-Kettering Cancer Center (MSKCC) reported in a single-centre series (n=1,589) a rate of 4.2% positive soft tissue surgical margins (STSM) compared to an average rate of 11.3% in a large meta-analysis across 36 studies (35,39). The authors from the MSKCC study showed that the five-year disease-specific survival (DSS) was significantly lower in the positive STSM group.
compared to the negative STSM group (32% vs. 72%) after RC (39). In addition, a systematic review by Hong et al. including 38,384 BC patients who underwent RC, found a significant association between positive STSM status and poor outcomes of OS, CSS, and RFS [summary relative risk estimates (SRRE) 1.68, 95% CI: 1.58–1.80; 1.82, 95% CI: 1.63–2.04; 1.63, 95% CI: 1.46–1.83; respectively], when compared to negative STSM status (35). Regarding these data, avoiding positive STSM status should be a primary target intraoperatively for every surgeon performing RC. Especially in centres with less experience and lower case-loads, surgeons should be alert during the dissection and use frozen section evaluation in case of any doubt (43).

Since positive STSM constitute a relevant factor that impacts survival, bladder dissection should be performed with caution, especially in the case of a large tumour. In case of any doubt, intraoperative frozen sections should be completed, especially urethral and ureteral sections. Ensuring negative STSM is therefore proposed as an essential quality indicator intraoperatively.

LND
To achieve the best possible eradication of local and regional cancer cells during surgery, radical cystectomy must be completed by a pelvic lymphadenectomy (7). Indeed, lymph node status was shown as a strong surrogate for predicting OS and RFS subsequent to RC (44). Since preoperative clinical staging or actual biomarkers are not accurate for detecting positive lymph nodes and CT scan sensitivity reaches only 53% (45), concomitant LND offers the most reliable pathological staging and helps identify high-risk patients who may benefit from further treatment (7). International and national guidelines recommend at least the dissection of a standard pelvic template, comprising lymphatic tissue around the common, internal and external iliac vessels as well as the obturator regions on both sides (7,12). Nevertheless, it was shown that a higher number of removed lymph nodes are associated with better survival without increasing complications (46,47). A recent RCT (LEA AUO AB 25/02 Trial), including 401 patients with T1G3 or T2-T4aM0 tumours, compared survival outcomes of limited (internal and external iliac plus bilateral obturator nodes) versus extended LND (additionally common iliac, bilateral deep obturator fossa, presacral, para- and interaorto-caval plus paraaortic lymph nodes up to the inferior mesenteric artery) (48). At 5 years, there was no significant difference between extended LND and limited LND regarding OS (5-year OS 59% vs. 50%; HR =0.78; P=0.12), CSS (5-year CSS 76% vs. 65%; HR =0.70; P=0.10) and RFS (5-year RFS 65% vs. 59%; HR =0.84; P=0.36) (48). Among the potential confounders, the inclusion of T1G3 patients (14%) might have biased the results. Shortly, results from the ongoing prospective phase-III-trial SWOG-1011 (NCT01224665) investigating standard/limited vs. extended LND only in MIBC patients are eagerly awaited. It remains true that a significant number of patients still do not receive any or a sub-standard lymphadenectomy despite the evidence and the guideline recommendations (49).

With regard to the available evidence, standard pelvic LND should be the absolute minimum to be performed during RC, but extended LND might be beneficial until proven otherwise. Adequacy of LND is proposed as another essential quality of care indicator for the management of MIBC.

Enhanced recovery after surgery (ERAS)
ERAS programs are based on multimodal and interdisciplinary protocols in order to standardize perioperative care and improve postoperative recovery and surgical outcomes of the patients(50,51). First described in colorectal surgery (52-54), ERAS programs have become crucial for uro-oncologic surgeries in recent years (55). For RC, accompanied by perioperative complications in up to two-thirds of the cases (56), ERAS strategies are of utmost interest. Therefore, the ERAS society established specific guidelines extrapolated from protocols of other specialities in order to transfer approved knowledge to this field (57). ERAS regimes are composed of multimodal domains, which may vary slightly between the different protocols and institutions. In general, they combine multiple preoperative (e.g., patient education, optimization of medical conditions, bowel preparation, carbohydrate loading), intraoperative (e.g., thrombosis and antimicrobial prophylaxis, avoidance of narcotic analgetics, optimized fluid management) and postoperative elements (e.g., ileus prevention, multimodal analgesia, early enteral nutrition and mobilization) (57-59). With the aim to aggregate varying results from previous studies, Tyson and Chang conducted a systematic review on ERAS strategies for RC in 2016 (60). They found a lower overall complication rate, shorter in-hospital length of stay (LOS), faster recovery to normal bowel function, and lower 30-d readmission rate for the ERAS group. However, no difference was found regarding the overall readmission rate (60). Another systematic review published 2020 by Williams et al. reported comparable results. Accordingly, the
authors found reduced LOS and postoperative complication rates for implementing ERAS strategies to RC (61). Moreover, accounting for the inter-provider variation of the programs, they described the avoidance of nasogastric tubes and the use of local anaesthesia as individual ERAS components to be associated with reduced LOS (61).

Even though ERAS protocols may not be uniform between institutions yet, their general implementation has been shown to accelerate postoperative re-convalescence while reducing complications rates, in-hospital stay and overall costs of RC. Therefore, we propose the inclusion of ERAS strategies in the perioperative management of patients undergoing RC as another key factor to ensure and compare the quality of this procedure.

**Smoking cessation counselling**

Cigarette smoking is the strongest modifiable risk factor for the carcinogenesis of BC (62-66). For non-muscle-invasive BC, several studies showed that ongoing smoking leads to worsened prognoses with disease-recurrence up to two-fold (67-71). For MIBC, the impact of continued cigarette consumption on survival outcomes after RC and on the efficacy of chemotherapy is gaining evidence.

A recently published systematic review from Cacciamani et al., including 17 studies comprising 13,777 patients, showed that ongoing smoking subsequently to RC increases risks of overall mortality (HR =1.21, 95% CI: 1.08–1.36; P=0.001), cancer-specific mortality (HR =1.24, 95% CI: 1.13–1.36; P<0.0001), and disease recurrence (HR =1.24, 95% CI: 1.12–1.38; P=0.0001) (72). Moreover, the authors demonstrated superior pCR rates (HR =0.47, 95% CI: 0.29–0.75; P=0.001) for non-, respective never-smoking patients after NAC compared to smokers (72). Comparable results were found in a recent prospective study (n=167) showing a significant association of current smoking with decreased odds of pCR [odds ratio (OR) 0.34, 95% CI: 0.13–0.85] and an increased probability of pathological non-response (OR =2.49, 95% CI: 1.02–6.06) after NAC (73). Therefore, there is an urgent need to educate smoking patients on these effects and offer cessation interventions as early as possible, starting at diagnosis (74,75). Indeed, the time of cancer diagnosis is a “teachable moment” for lifestyle changes (76), and cancer patients are more likely to stop smoking than patients without a cancer diagnosis (77,78).

The beneficial effect of smoking cessation on the prognosis of MIBC has been investigated in several studies. Rink et al. showed in a retrospective study of 1,506 patients treated with RC that smoking cessation over ten years significantly decreases the risks of overall mortality (HR =0.69; P=0.012), cancer-specific mortality (HR =0.42; P<0.001), and disease recurrence (HR =0.44; P<0.001) (79). Moreover, several prospective studies investigating the potential effect of smoking cessation in MIBC patients are still ongoing. For example, the multicenter randomized STOP-OP trial (Intensive Smoking and Alcohol Cessation Intervention in Bladder Cancer Surgery Patients, NCT02188446) used a smoking cessation specific programme (Gold Standard Programme), which combines a 6-week behavioural education with pharmacotherapeutic strategies (i.e., nicotine replacement) (80). Besides, shorter programs (i.e., Come & Quit, crash courses, brief intervention) are available and also effective. These programs should be promoted to obtain the highest rate of smoking cessation in patients who suffer from bladder cancer (80).

Since there is evidence for improved cancer-specific and general survival outcomes through smoking cessation, we advocate pro-active smoking cessation counselling provided by health care providers along the treatment process of MIBC for every actual smoker as another quality indicator for clinical practices.

**The Bladder Cancer Quality Score (BC-QS)**

A retrospective study using the National Cancer Database (NCDB) evaluated NAC, LND, and STSM as potential quality indicators for BC treatment in 48,341 patients who underwent RC and led to a composition of the BC-QS. Interestingly, better performance in this score was associated with a significantly lower 30-day, 90-day, and overall mortality of patients after RC (adjusted OR =0.78, 95% CI: 0.64–0.96; OR =0.84, 95% CI: 0.72–0.97 and HR 0.86, 95% CI: 0.81–0.92, respectively) (17). These findings may support the relevance of the proposed indicators for an optimized care-taking of MIBC patients. Moreover, combining separate indicators into simply applicable scoring systems may increase the application in clinical practices and facilitate quality measurements and comparison. Additionally, composite measures through scores improve both the reliability of quality measurements and predicting hospital performances (81).

**Conclusions**

Providing optimal care for MIBC patients remains
challenging, and a large variety of treatment outcomes indicates the need of establishing disease-specific quality measurements. We propose five key indicators for the perioperative quality management of MIBC that include the use of NAC with cisplatin-based combination regimes in eligible patients, performance of at least a standard pelvic template LND, avoidance of positive STSM, implementation of ERAS strategies, and offering smoking cessation counselling to every active smoker. Both the adherence and measurement of these indicators would allow for an improvement of care-taking, survival, and comparability of performances. Combining these factors into simple-to-capture scores could increase application rates and would allow for a validated metric correlation of expectable survival outcomes and hospital quality (Table 2).

**Table 2** Quality of care indicators for the management of MIBC perioperatively to RC

| Time               | Quality indicator                             | Recommendation                                                                 | Technique/extent/regime                                                                 |
|--------------------|-----------------------------------------------|--------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------|
| Preoperative       | Utilization of NAC                            | Provide NAC to all clinically eligible MIBC (≥T2) patients prior to RC           | Cisplatin-based combination therapies                                                   |
| intraoperative     | Performance of an adequate LND               | Perform LND during every RC for improved disease control and accurate nodal-staging | At least by following a standard pelvic template; potentially extended                  |
| Postoperative      | Proportion of negative soft tissue surgical margins | Ensure negative soft tissue margins on final pathological specimen                 | Reasonable wide surgical excision; secured by intraoperative frozen section consultation when in doubt |
| Along the treatment| Implementation of ERAS programs              | Standardize perioperative care by providing ERAS strategies to all patients undergoing RC | Following multimodal and interdisciplinary protocols as proposed by the ERAS society |
|                    | Provision of smoking cessation advice         | Offer pro-active cessation counselling to all smokers along the treatment process for BC | Behavioral and pharmacologic strategies (i.e., nicotine replacement, benzodiazepines for withdrawal symptoms); Short-term interventions and established programs (i.e., the Gold Standard Program, Come & Quit, Crash courses, etc.) |

NAC, neoadjuvant chemotherapy; MIBC, muscle-invasive bladder cancer; RC, radical cystectomy; LND, lymph node dissection; ERAS, enhanced recovery after surgery.

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tcr.amegroups.com/article/view/10.21037/tcr-21-1116/coif). MR serves as an unpaid editorial board member of *Translational Cancer Research* from November 2021 to October 2023. The other authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

Acknowledgments

**Funding:** EI is supported by the Eusp Scholarship of the European Association of Urology (EAU). NCG is supported by the Zurich Cancer League.

**Footnote**

*Reporting Checklist:* The authors have completed the Narrative Review reporting checklist. Available at https://tcr.amegroups.com/article/view/10.21037/tcr-21-1116/rc

**References**

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020;70:7-30.
2. Teoh JY, Huang J, Ko WY, et al. Global Trends of Bladder
Cancer Incidence and Mortality, and Their Associations with Tobacco Use and Gross Domestic Product Per Capita. Eur Urol 2020;78:893-906.

3. Putluri N, Shojaei A, Vasu VT, et al. Metabolomic profiling reveals potential markers and bioprocesses altered in bladder cancer progression. Cancer Res 2011;71:7376-86.

4. Shariat SF, Kim J, Raptidis G, et al. Association of p53 and p21 expression with clinical outcome in patients with carcinoma in situ of the urinary bladder. Urology 2003;61:1140-5.

5. Svatek RS, Shariat SF, Novara G, et al. Discrepancy between clinical and pathological stage: external validation of the impact on prognosis in an international radical cystectomy cohort. BJU Int 2011;107:898-904.

6. Sylvester RJ, Rodríguez O, Hernández V, et al. European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel. Eur Urol 2021;79:480-8.

7. Witjes JA, Bruins HM, Cathomas R, et al. EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer. Milan: EAU Annual Congress, 2021.

8. Chang SS, Bochner BH, Chou R, et al. Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline. J Urol 2017;198:552-9.

9. Babjuk M, Burger M, Compérat E, et al. EAU Guidelines on Non-muscle-invasive Bladder Cancer (T4T1 and CIS). Milan: EAU Annual Congress, 2021.

10. Chang SS, Boorjian SA, Chou R, et al. Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline. J Urol 2016;196:1021-9.

11. Flait TW, Spiess PE, Agarwal N, et al. NCCN Guidelines Insights: Bladder Cancer, Version 5.2018. J Natl Compr Canc Netw 2018;16:1041-53.

12. Leow JJ, Bedke J, Chaimie K, et al. SIU-ICUD consultation on bladder cancer: treatment of muscle-invasive bladder cancer. World J Urol 2019;37:61-83.

13. Monteiro LL, Witjes JA, Agarwal PK, et al. ICUD-SIU International Consultation on Bladder Cancer 2017: management of non-muscle invasive bladder cancer. World J Urol 2019;37:51-60.

14. Groeben C, Koch R, Baumacke M, et al. In-Hospital Outcomes after Radical Cystectomy for Bladder Cancer: Comparing National Trends in the United States and Germany from 2006 to 2014. Urol Int 2019;102:284-92.

15. Hedgepeth RC, Zhang Y, Skolarus TA, et al. Variation in use of lymph node dissection during radical cystectomy for bladder cancer. Urology 2011;77:385-90.

16. Novara G, Catto JW, Wilson T, et al. Systematic review and cumulative analysis of perioperative outcomes and complications after robot-assisted radical cystectomy. Eur Urol 2015;67:376-401.

17. Khanna A, Saarela O, Lawson K, et al. Hospital Quality Metrics for Radical Cystectomy: Disease Specific and Correlated to Mortality Outcomes. J Urol 2019;202:490-7.

18. Ehdaie B, Atoria CL, Lowrance WT, et al. Adherence to surveillance guidelines after radical cystectomy: a population-based analysis. Urol Oncol 2014;32:779-84.

19. Zaffuto E, Bandini M, Gazdovich S, et al. Contemporary rates of adherence to international guidelines for pelvic lymph node dissection in radical cystectomy: a population-based study. World J Urol 2018;36:1417-22.

20. Schroack FR, Smith N, Shelton JB. Implementing risk-aligned bladder cancer surveillance care. Urol Oncol 2018;36:257-64.

21. Ghoneim MA, el-Mekresh MM, el-Baz MA, et al. Radical cystectomy for carcinoma of the bladder: critical evaluation of the results in 1,026 cases. J Urol 1997;158:393-9.

22. Bassi P, Ferrante GD, Piazza N, et al. Prognostic factors of outcome after radical cystectomy for bladder cancer: a retrospective study of a homogeneous patient cohort. J Urol 1999;161:1494-7.

23. Dalbagni G, Genega E, Hashibe M, et al. Cystectomy for bladder cancer: a contemporary series. J Urol 2001;165:1111-6.

24. Stein JP, Skinner DG. Radical cystectomy for invasive bladder cancer: long-term results of a standard procedure. World J Urol 2006;24:296-304.

25. Mari A, Campi R, Tellini R, et al. Patterns and predictors of recurrence after open radical cystectomy for bladder cancer: a comprehensive review of the literature. World J Urol 2018;36:157-70.

26. Isbarn H, Jeldres C, Zini L, et al. A population based assessment of perioperative mortality after cystectomy for bladder cancer. J Urol 2009;182:70-7.

27. Hanna N, Trinh QD, Seisen T, et al. Effectiveness of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer in the Current Real World Setting in the USA. Eur Urol Oncol 2018;1:83-90.

28. Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003;349:859-66.
29. Yin M, Joshi M, Meijer RP, et al. Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Systematic Review and Two-Step Meta-Analysis. Oncologist 2016;21:708-15.

30. Pfister C, Gravis G, Fléchon A, et al. Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses. Eur Urol 2021;79:214-21.

31. Necchi A, Anichini A, Raggi D, et al. Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study. J Clin Oncol 2018;36:3353-60.

32. Svatek RS, Shariat SF, Lasky RE, et al. The effectiveness of off-protocol adjuvant chemotherapy for patients with urothelial carcinoma of the urinary bladder. Clin Cancer Res 2010;16:4461-7.

33. Bajorin DF, Witjes JA, Gschwend JE, et al. Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Bladder Carcinoma. Oncologist 2016;21:708-15.

34. Lucca I, Rouprêt M, Kluth L, et al. Adjuvant cisplatin-based combined chemotherapy for lymph node (LN)-positive urothelial carcinoma of the bladder (UCB) after radical cystectomy (RC): a retrospective international study of >1500 patients. BJU Int 2015;115:722-7.

35. Hong X, Li T, Ling F, et al. Impact of surgical margin status on the outcome of bladder cancer treated by radical cystectomy: a meta-analysis. Oncotarget 2017;8:17258-69.

36. Xylinas E, Rink M, Novara G, et al. Predictors of survival in patients with soft tissue surgical margin involvement at radical cystectomy. Ann Surg Oncol 2013;20:1027-34.

37. Novara G, Svatek RS, Shariat SF, Lasky RE, et al. The effectiveness of off-protocol adjuvant chemotherapy for patients with urothelial carcinoma of the urinary bladder. Clin Cancer Res 2010;16:4461-7.

38. Bajorin DF, Witjes JA, Gschwend JE, et al. Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Bladder Carcinoma. Oncologist 2016;21:708-15.

39. Dotan ZA, Kavanagh K, Yossepowitch O, et al. Positive surgical margins in soft tissue following radical cystectomy for bladder cancer and cancer specific survival. J Urol 2007;178:2308-12; discussion 2313.

40. Canter D, Guzzo TJ, Resnick MJ, et al. A thorough pelvic lymph node dissection in presence of positive margins associated with better clinical outcomes in radical cystectomy patients. Urology 2009;74:161-5.

41. Raj GV, Tal R, Vickers A, et al. Significance of intraoperative ureteral evaluation at radical cystectomy for urothelial cancer. Cancer 2006;107:2167-72.

42. Motlagh RS, Mori K, Aydh A, et al. Impact of hospital and surgeon volumes on short-term and long-term outcomes of radical cystectomy. Curr Opin Urol 2020;30:701-10.

43. Laukhtina E, Rajwa P, Mori K, et al. Accuracy of Frozen Section Analysis of Urethral and Ureteral Margins During Radical Cystectomy for Bladder Cancer: A Systematic Review and Diagnostic Meta-Analysis. Eur Urol Focus 2021. [Epub ahead of print]. doi: 10.1016/j.euf.2021.05.010.

44. Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001;19:666-75.

45. Horn T, Zahel T, Adt N, et al. Evaluation of Computed Tomography for Lymph Node Staging in Bladder Cancer Prior to Radical Cystectomy. Urol Int 2016;96:51-6.

46. D’Andrea D, Abufaraj M, Soria F, et al. Association of super-extended lymphadenectomy at radical cystectomy with perioperative complications and re-hospitalization. World J Urol 2020;38:121-8.

47. Gschwend JE, Heck MM, Lehmann J, et al. Extended Versus Limited Lymph Node Dissection in Bladder Cancer Patients Undergoing Radical Cystectomy: Survival Results from a Prospective, Randomized Trial. Eur Urol 2019;75:604-11.

48. Hollenbeck BK, Ye Z, Wong SL, et al. Hospital lymph node counts and survival after radical cystectomy. Cancer 2008;112:806-12.

49. Kehlet H, Wilmore DW. Multimodal strategies to improve surgical outcome. Am J Surg 2002;183:630-41.

50. Kehlet H. Multimodal approach to control postoperative pathophysiology and rehabilitation. Br J Anaesth 1997;78:606-17.

51. Lemanu DP, Singh PP, Stowers MD, et al. A systematic review to assess cost effectiveness of enhanced recovery after surgery programmes in colorectal surgery. Colorectal Dis 2014;16:338-46.

52. Kehlet H, Dahl JB. Anaesthesia, surgery, and challenges in postoperative recovery. Lancet 2003;362:1921-8.
54. Kehlet H. Fast-track colorectal surgery. Lancet 2008;371:791-3.
55. Patel HR, Cerantola Y, Valerio M, et al. Enhanced recovery after surgery: are we ready, and can we afford not to implement these pathways for patients undergoing radical cystectomy? Eur Urol 2014;65:263-6.
56. Shabsigh A, Korets R, Vora KC, et al. Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology. Eur Urol 2009;55:164-74.
57. Cerantola Y, Valerio M, Persson B, et al. Guidelines for perioperative care after radical cystectomy for bladder cancer: Enhanced Recovery After Surgery (ERAS®) society recommendations. Clin Nutr 2013;32:879-87.
58. Pozo C, Shariat SF, D’Andrea D, et al. Enhanced Recovery after Radical Cystectomy. Curr Opin Urol 2019;29:227-38.
59. Pang KH, Groves R, Venugopal S, et al. Prospective Implementation of Enhanced Recovery After Surgery Protocols to Radical Cystectomy. Eur Urol 2018;73:363-71.
60. Tyson MD, Chang SS. Enhanced Recovery Pathways Versus Standard Care After Cystectomy: A Meta-analysis of the Effect on Perioperative Outcomes. Eur Urol 2016;70:995-1003.
61. Williams SB, Cumberbatch MGK, Kamat AM, et al. Reporting Radical Cystectomy Outcomes Following Implementation of Enhanced Recovery After Surgery Protocols: A Systematic Review and Individual Patient Data Meta-analysis. Eur Urol 2020;78:719-30.
62. Freedman ND, Silverman DT, Hollenbeck AR, et al. Association between smoking and risk of bladder cancer among men and women. JAMA 2011;306:737-45.
63. Kuper H, Boffetta P, Adami HO. Tobacco use and cancer causation: association by tumour type. J Intern Med 2002;252:206-24.
64. Gallawey MS, Henley SJ, Steele CB, et al. Surveillance for Cancers Associated with Tobacco Use - United States, 2010-2014. MMWR Surveill Summ 2018;67:1-42.
65. Islami F, Goding Sauer A, Miller KD, et al. Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States. CA Cancer J Clin 2018;68:31-54.
66. Lenis AT, Lec PM, Chamek K, et al. Bladder Cancer: A Review. JAMA 2020;324:1980-91.
67. Aveyard P, Adab P, Cheng KK, et al. Does smoking status influence the prognosis of bladder cancer? A systematic review. BJU Int 2002;90:228-39.
68. Fleshner N, Garland J, Moadel A, et al. Influence of smoking status on the disease-related outcomes of patients with tobacco-associated superficial transitional cell carcinoma of the bladder. Cancer 1999;86:2337-45.
69. Lammers RJ, Witjes WP, Hendricksen K, et al. Smoking status is a risk factor for recurrence after transurethral resection of non-muscle-invasive bladder cancer. Eur Urol 2011;60:713-20.
70. Rink M, Furberg H, Zabor EC, et al. Impact of smoking and smoking cessation on oncologic outcomes in primary non-muscle-invasive bladder cancer. Eur Urol 2013;63:724-32.
71. Crivelli JJ, Xylinas E, Kluth LA, et al. Effect of smoking on outcomes of urothelial carcinoma: a systematic review of the literature. Eur Urol 2014;65:742-54.
72. Cacciamani GE, Ghodoussipour S, Mari A, et al. Association between Smoking Exposure, Neoadjuvant Chemotherapy Response and Survival Outcomes following Radical Cystectomy: Systematic Review and Meta-Analysis. J Urol 2020;204:649-60.
73. Gild P, Vetterlein MW, Seiler R, et al. The association of cigarette smoking and pathological response to neoadjuvant platinum-based chemotherapy in patients undergoing treatment for urinary bladder cancer - A prospective European multicenter observational study of the EAU Young Academic Urologists (YAU) urothelial carcinoma working group. Surg Oncol 2020;34:312-7.
74. Mori K, Mostafaei H, Abuafaraj M, et al. Smoking and bladder cancer: review of the recent literature. Curr Opin Urol 2020;30:720-5.
75. Janisch F, Shariat SF, Schernhammer E, et al. The interaction of gender and smoking on bladder cancer risks. Curr Opin Urol 2019;29:249-55.
76. Demark-Wahnefried W, Aziz NM, Rowland JH, et al. Riding the crest of the teachable moment: promoting long-term health after the diagnosis of cancer. J Clin Oncol 2005;23:5814-30.
77. Gritz ER, Fingeret MC, Vidrine DJ, et al. Successes and failures of the teachable moment: smoking cessation in cancer patients. Cancer 2006;106:17-27.
78. Bassett JC, Gore JL, Chi AC, et al. Impact of a bladder cancer diagnosis on smoking behavior. J Clin Oncol 2012;30:1871-8.
79. Rasmussen M, Fernández E, Tønnesen H. Effectiveness of the Gold Standard Programme compared with other
smoking cessation interventions in Denmark: a cohort study. BMJ Open 2017;7:e013553.
81. Dimick JB, Birkmeyer NJ, Finks JF, et al. Composite measures for profiling hospitals on bariatric surgery performance. JAMA Surg 2014;149:10-6.

Cite this article as: König F, Pradere B, Grossmann NC, Quhal F, Rajwa P, Laukhtina E, Mori K, Katayama S, Yanagisawa T, Mostafai H, Motlagh RS, Aydh A, Dahlem R, Shariat SF, Rink M. Quality indicators for the management of muscle-invasive bladder cancer in the perioperative setting of radical cystectomy: a narrative review. Transl Cancer Res 2022;11(4):908-917. doi: 10.21037/tcr-21-1116